Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal

Home page

Superovulating mares with gonadotrophins : recent developments and state of the art

2007, INRA Prod. Anim., 20, 275-294

C. BRIANT, D. GUILLAUME, P.-L. TOUTAIN, M.-R. BLANC

INRA, CNRS, Université de Tours, Haras Nationaux, UMR85 Physiologie de la Reproduction et des Comportements, F-37380 Nouzilly, France

Abstract 

In domestic species the aim of superovulation treatments is to increase natural ovulation rates in order to produce several healthy embryos in a single oestrus cycle and to then transfer these embryos into recipient females. Actually, in equine species, no commercial preparation is available for superovulation. Indeed, gonadotrophins licenced for other species are not effective in mares and responses in mares, to superovulation treatments with equine FSH (eFSH) are heterogeneous.

In mares, superovulation treatments must use eFSH and the heterogeneity of response can adversely affect the number of preovulatory follicles, the number of ovulations and the number of transferable embryos. As for other domestic species, there are multiple reasons for this variability. Among them, unsatisfactory dosage regimens for eFSH that can cause unwanted effects on follicular growth, ovulation and plasma hormone levels and decrease embryo production. In this context, our studies in mares have determined the relationships between impaired follicular growth and modified plasma hormone levels and the factors responsible for the decrease in embryo production. An appropriate dosage regimen for eFSH has been proposed on the basis of FSH plasma levels that can induce superovulation without unwanted side effects. This dosage regimen corresponds to 50% of the daily production rate of the native hormone in an ova riectomized mare. On the basis of these data, a treatment regimen has been suggested, with the aim of producing 3 to 4 ovulations and 1,8 to 2,5 embryos per oestrus cycle. Finally, several strategies have been suggested which could improve the effectiveness of eFSH treatments in mares.

Nevertheless, the future commercialization of an equine FSH preparation is questionnable because the number of pituitary glands available from slaughterhouses is limited, there are strong health requirements associated with this type of product and this preparation has to be species specific.

Download documents